API
< Back to all clusters
[HEALTH] · South Korea, United States · 3 sources

started · updated

Chong Kun Dang presents preclinical results for CKD-DAC anticancer candidate

Chong Kun Dang presented preclinical research results for its next-generation anticancer drug candidate, CKD-DAC, at the 17th World ADC San Diego conference. CKD-DAC is a Degrader-Antibody Conjugate (DAC) that combines a self-developed cyclin K (CCNK) molecular glue degrader with a target antibody.

Unlike traditional Antibody-Drug Conjugates (ADCs) that use cytotoxic drugs to attack cancer cells directly, DACs use a payload to degrade specific proteins essential for cancer cell survival. In preclinical studies, the CKD-DAC payload maintained efficacy even in cell lines resistant to trastuzumab deruxtecan. It also demonstrated synergistic effects when used in combination with the PARP inhibitor olaparib.

In animal models, CKD-DAC showed tumor suppression levels comparable to trastuzumab deruxtecan. Notably, in toxicity tests conducted on rats, the CKD-DAC group showed no hematological toxicity, whereas the trastuzumab deruxtecan group exhibited such toxicity. The company plans to expand its DAC platform to develop various differentiated anticancer drugs.

Entities

Chong Kun Dang